Psilocybin-Research.com
Searchable psilocybin and psilocin bibliometrics.
Executed search
Keyword: Addictive
57 matching records are displayed.
Clear search
Hofmann vs. Paracelsus: Do Psychedelics Defy the Basics of Toxicology?-A Systematic Review of the Main Ergolamines, Simple Tryptamines, and Phenylethylamines.
Psychedelics are experiencing a strong renaissance and will soon be incorporated into clinical practice. However, there is uncertainty about how much harm they can cause at what doses. This review aimed to collect information on the health-hazardous doses of psychedelic substances, to be aware of the risks to which patients may be subjected. We focused on er...
Are psychedelics the answer to chronic pain: A review of current literature.
AimsWe aim to provide an evidence-based overview of the use of psychedelics in chronic pain, specifically LSD and psilocybin.ContentChronic pain is a common and complex problem, with an unknown etiology. Psychedelics like lysergic acid diethylamide (LSD) and psilocybin, may play a role in the management of chronic pain. Through activation of the serotonin-2A...
The psychedelic renaissance: can psilocybin possibly combat depression?
Mental health disorders such as depression and anxiety are major contributors to the overall global health burden. COVID-19 has further aggravated mental health disorders and also increased substance abuse due to lockdowns1. The Global Burden of Disease reported that the pandemic has led to a 27.6% increase in cases of major depressive disorder (MDD) and a 2...
Use of plant-based hallucinogens and dissociative agents: U.S. Time Trends, 2002-2019.
AimsInformation on time trends in use of different plant-based hallucinogens is lacking. The current study used nationally representative U.S. data to assess overall and age-specific time trends in the prevalence of lifetime and 12-month use of plant-based hallucinogens and dissociative agents.MethodsParticipants were respondents aged ≥ 12 years (N = 1,006,0...
Acute and long-term effects of psilocybin on energy balance and feeding behavior in mice.
Psilocybin and other serotonergic psychedelics have re-emerged as therapeutics for neuropsychiatric disorders, including addiction. Psilocybin induces long-lasting effects on behavior, likely due to its profound ability to alter consciousness and augment neural connectivity and plasticity. Impaired synaptic plasticity in obesity contributes to 'addictive-lik...
Psilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy.
Psilocybin is a tryptamine alkaloid found in some mushrooms, especially those of the genus Psilocybe. Psilocybin has four metabolites including the pharmacologically active primary metabolite psilocin, which readily enters the systemic circulation. The psychoactive effects of psilocin are believed to arise due to the partial agonist effects at the 5HT2A rece...
Neuropharmacological analysis of the anti-addictive and therapeutic effects of psilocybin
This review presents a general background of psilocybin pharmacology and discusses its uses in treating various mental health disorders such as depression, anxiety, obsessive-compulsive disorder, and addiction. A summary of preliminary clinical trials utilizing psilocybin in each disorder is presented, along with an analysis of the neurobiological mechanisms...
Mycotherapy: Potential of Fungal Bioactives for the Treatment of Mental Health Disorders and Morbidities of Chronic Pain.
Mushrooms have been used as traditional medicine for millennia, fungi are the main natural source of psychedelic compounds. There is now increasing interest in using fungal active compounds such as psychedelics for alleviating symptoms of mental health disorders including major depressive disorder, anxiety, and addiction. The anxiolytic, antidepressant and a...
Psilocybin-Induced Mystical-Type Experiences are Related to Persisting Positive Effects: A Quantitative and Qualitative Report.
Psychedelic drugs such as psilocybin have shown substantial promise for the treatment of several psychiatric conditions including mood and addictive disorders. They also have the remarkable property of producing persisting positive psychological changes in healthy volunteers for at least several months. In this study (NCT03289949), 35 medium-high doses of ps...
Classic Psychedelics in Addiction Treatment: The Case for Psilocybin in Tobacco Smoking Cessation.
This manuscript reviews research suggesting that classic psychedelics (5-HT2A receptor agonists) are effective in treating addictions including tobacco use disorder. I review historical research from the 1950s to 1970s suggesting that classic psychedelics are associated with addiction recovery across pharmacologically distinct drugs of addiction. I then revi...
Researchers hope psilocybin could improve quit rates for smokers
With nicotine being one of the most addictive substances and the available treatments for nicotine addiction leading to no better than a 30% success rate, it's no wonder that a newly announced multisite study of the psychedelic psilocybin for smoking cessation is generating excitement. While taking care not to oversell the potential of this strategy, those i...
Psychedelics and psychiatric disorders: A emerging role
Introduction Recently there has been renewal in interest of psychedelic research. Classic psychedelics such as lysergic acid diethylamide (LSD), psilocybin and mescaline act pharmacologically as agonists at the 5-HT2A receptor. The entactogens like methylenedioxymethamphetamine (MDMA), acts as a serotonin, dopamine and noradrenaline agonist. All of these dru...
Treating addiction with psychedelics - are we waking up?
Introduction Classic psychedelics have been administered in sacramental contexts since ancient times. They were of prominent interest within psychiatry and neuroscience in the 1950s to 1960s, but the association between classic psychedelics and the emerging counterculture put an end to their research. Modern research with classic psychedelics has reinitiated...
Psychedelics: A new era of treatment?
Introduction Psychedelics - including LSD (lysergic acid diethylamide), psilocybin, DMT (N, N-dimethyltryptamine), ayahuasca and mescaline - have an ancient history across various civilizations. In 1950, after LSD’s discovery by Hofmann, psychedelics enjoyed a short-lived relationship with psychiatry, before prohibitive legislature emerging in response to th...
A Case Series Describing the Tale of ‘The Magic Mushroom’; An Increasing Trend of Psychedelic Misuse Among Substance Abusers in Terengganu
Hallucinogens comprise of a vast amount of substances such as Lysergic Acid Diethylamide, Phenylcyclidine PCP, naturally occurring alkaloid like Belladona and even mushrooms such as psylocybins. Usage of these substances can be traced back to antiquity, serving various purpose such as spiritual rites or even recreational purposes. However, in the modern era,...
Psychedelic perceptions: mental health service user attitudes to psilocybin therapy.
IntroductionDespite the rapid advance of psychedelic science and possible translation of psychedelic therapy into the psychiatric clinic, very little is known about mental health service user attitudes.ObjectivesTo explore mental health service user attitudes to psychedelics and psilocybin therapy.MethodsA questionnaire capturing demographics, diagnoses, pre...
Psychedelics and health behaviour change.
Healthful behaviours such as maintaining a balanced diet, being physically active and refraining from smoking have major impacts on the risk of developing cancer, diabetes, cardiovascular diseases and other serious conditions. The burden of the so-called 'lifestyle diseases'-in personal suffering, premature mortality and public health costs-is considerable. ...
Clinical and biological predictors of psychedelic response in the treatment of psychiatric and addictive disorders: A systematic review.
The use of psychedelic treatments has shown very promising results in some psychiatric and addictive disorders, but not all patients achieved a response. The aim of this review is to explore the clinical and biological factors which could predict the response to psychedelics in psychiatric and addictive disorders. A systematic research was performed on MEDLI...
Psychedelics and Health Behavior Change - Journal of Psychopharmacology (in press)
Healthful behaviors such as maintaining a balanced diet, being physically active, and refraining from smoking have major impacts on the risk of developing cancer, diabetes, cardiovascular diseases, and other serious conditions. The burden of the so-called “lifestyle diseases” - in personal suffering, premature mortality, and public health costs - is consider...